Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Tumor Biology

• Publication date

  2015-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-014-3030-6PMID 25577247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arginase‐1 is a more sensitive marker of hepatic differentiation than HepPar‐1 and glypican‐3 in fine‐needle aspiration biopsies

  2012cited by this paper
• Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.

  2012cited by this paper
• Arginase‐1: A novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology

  2012cited by this paper
• The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• Arginase-1: A New Immunohistochemical Marker of Hepatocytes and Hepatocellular Neoplasms

  2010cited by this paper
• Glypican-3: A Novel Diagnostic Marker for Hepatocellular Carcinoma and More

  2009cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.

  2009cited by this paper
• Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.

  2009cited by this paper
• Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

  2008cited by this paper
• Expression of glypican 3 in ovarian and extragonadal germ cell tumors.

  2008cited by this paper
• Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.

  2008cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• HepPar1, MOC-31, pCEA, mCEA and CD10 for Distinguishing Hepatocellular Carcinoma vs. Metastatic Adenocarcinoma in Liver Fine Needle Aspirates

  2006cited by this paper
• Oncofetal protein glypican-3 in testicular germ-cell tumor

  2006cited by this paper
• Glypican 3: A Novel Marker in Testicular Germ Cell Tumors

  2006cited by this paper
• New immunohistochemical markers in testicular tumors.

  2006cited by this paper
• Hep Par 1 Antibody Stain for the Differential Diagnosis of Hepatocellular Carcinoma: 676 Tumors Tested Using Tissue Microarrays and Conventional Tissue Sections

  2003cited by this paper
• Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.

  2003cited by this paper
• Hepatocyte Antigen as a Marker of Hepatocellular Carcinoma: An Immunohistochemical Comparison to Carcinoembryonic Antigen, CD10, and Alpha-Fetoprotein

  2002cited by this paper
• Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.

  2002cited by this paper
• Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma

  1998cited by this paper
• Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors.

  1997cited by this paper
• The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer

  1995cited by this paper
• The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.

  1995cited by this paper

• Research Progress on the Relationship between the Biological Characteristics of CD13, CD28, and ARG-1 and Digestive Tract Malignant Tumors

  2025cites this paper
• Ethanolamine-phosphate phospho-lyase (ETNPPL) contributes to the diagnosis, prognosis, and therapy of hepatocellular carcinoma

  2023cites this paper
• Ancillary Tests for Hepatocellular Carcinoma

  2022cites this paper
• Role of arginase 1 immunohistochemical marker in differentiating hepatocellular carcinoma from other primary and secondary carcinomas of the liver, a tissue microarray study

  2022cites this paper
• Hepatoid prostatic carcinoma with adrenal metastasis and novel genetic alterations

  2022cites this paper
• Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma cubtypes and exclusion of the metastases.

  2021cites this paper
• Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma

  2021cites this paper
• The significance of arginase-1 expression in the diagnosis of liver cancer

  2020cites this paper
• Downregulation of ARG 2 inhibits growth of colorectal cancer cells and increases expression of the CD 3 ζ chain in co-cultured T-cells

  2019cites this paper
• The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver

  2019cites this paper
• The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection

  2019cites this paper
• The Diagnostic Role of Arginase-1, MOC-31, and CDX2 in the Differentiation of Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colonic Carcinoma of the Liver

  2019cites this paper
• High-throughput three-dimensional spheroid tumor model using a novel stamp-like tool

  2019cites this paper
• Immunohistochemical panel of glypican-3, hepatocyte paraffin antigen-1, arginase-1, cytokeratin-19, and human epithelial membrane antigen for the differential diagnosis of liver tumors

  2019influential citation
• The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection

  2019cites this paper
• The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection

  2019cites this paper
• Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

  2018cites this paper
• Ancillary tests in the diagnosis of liver and pancreatic neoplasms

  2018cites this paper
• Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas.

  2018cites this paper
• Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis

  2017cites this paper
• Immunohistochemistry, carcinomas of unknown primary, and incidence rates.

  2017cites this paper
• Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma

  2017cites this paper
• Detection of Hepatocellular Carcinoma Biomarker Golgi Protein 73 Based on Magnetic Enzyme-Linked Immunoassay.

  2017cites this paper
• Ductular reaction, cytokeratin 7 positivity, and gamma-glutamyl transferase in multistage hepatocarcinogenesis in rats

  2017cites this paper
• A subset of well-differentiated hepatocellular carcinomas are Arginase-1 negative.

  2017influential citation
• In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue.

  2016cites this paper
• Hepatocyte differentiation markers in adenocarcinoma of the prostate: hepatocyte paraffin 1 but not arginase-1 is specifically expressed in a subset of prostatic adenocarcinoma.

  2016cites this paper
• Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct – a potential novel tool for differential diagnosis of indeterminate biliary stricture

  2016cites this paper
• Value of the combined detection arginase-1 and glypican-3 expression in distinguishing hepatocellular carcinoma from metastatic tumors

  2016cites this paper
• Beta 2-Glycoprotein I in Hepatitis B virus infection patients with hepatocellular carcinoma , chronic hepatitis B and acute hepatitis B

  2016cites this paper
• Aspects of Hepatocellular Tumor Pathology

  2016cites this paper
• Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver

  2015influential citation
• sFRP-4, a potential novel serum marker for chronic hepatitis B-related hepatocellular carcinoma.

  2015cites this paper